The C-terminal region of the M-protein of Streptococcus pyogenes is a major target for vaccine development. The major feature is the C-repeat region, consisting of 35-42 amino acid repeat units that display high but not perfect identity. SV1 is a S. pyogenes vaccine candidate that incorporates five 14mer amino acid sequences (called J14 i variants) from differing Crepeat units in a single recombinant construct. Here we show that the J14 i variants chosen for inclusion in SV1 are the most common variants in a dataset of 176 unique M-proteins. Murine antibodies raised against SV1 were shown to bind to each of the J14 i variants present in SV1, as well as variants not present in the vaccine. Antibodies raised to the individual J14 i variants were also shown to bind to multiple but different combinations of J14 i variants, supporting the underlying rationale for the design of SV1. A Lewis Rat Model of valvulitis was then used to assess the capacity of SV1 to induce deleterious immune response associated with rheumatic heart disease. In this model, both SV1 and the M5 positive control protein were immunogenic. Neither of these antibodies were cross-reactive with cardiac myosin or collagen. Splenic T cells from SV1/CFA and SV1/alum immunized rats did not proliferate in response to cardiac myosin or collagen. Subsequent histological examination of heart tissue showed that 4 of 5 mice from the M5/CFA group had valvulitis and inflammatory cell infiltration into valvular tissue, whereas mice immunised with SV1/CFA, SV1/alum showed no sign of valvulitis. These results suggest that SV1 is a safe vaccine candidate that will elicit antibodies that recognise the vast majority of circulating GAS M-types.
Introduction

Materials and Methods
Bacteria, proteins and peptides
The GAS strains used in this study (Table 1 ) have all previously been described [20, 24, 25] . They represent 9 different emm-types, and one emm-negative strain. The strains also represent each of the major clusters proposed as part of the new emm-types clustering system [20] . All isolates were grown in sterile Todd Hewitt Broth supplemented with 1% neopeptone or on Columbia Blood agar containing 5% sterile horse blood. Recombinant proteins were expressed in Escherichia coli and purified using nickel affinity chromatography. Peptides were synthesized to 95% purity by Mimotopes (Table 2) .
Murine immunization
Female six-week old BALB/c mice (Animal Resources Centre, Perth, Australia) were subcutaneously immunized with 25μg of antigen admixed in a 1:1 ratio with alum delivered in a final 50μ volume. Secondary, tertiary and quaternary boosts consisting of 10μg protein emulsified 1:1 with aluminium hydroxide were delivered on days 21 and 28 and 35. Blood was collected prior to each immunization and 7 days after the final immunization. Sera from the final bleed was used in all assays reported here. All murine work was approved by the QIMR Berghofer Animal Ethics Research Committee (A0311-641).
Secondary structure
The secondary structure of 14mer peptides in solution was investigated by circular dichromic spectra acquired with a JASCO J-715 CD Spectropolarimeter at 20°C. Peptide solutions were assessed at 0.02 mg/mL in 10 mM sodium phosphate, 20 mM NaCl, pH 8.0. Far UV-CD spectra were acquired at from 260 to 190 nm in 0-50% 2,2-trifluoroethanol (TFE). All spectra were corrected for buffer baseline and converted to mean residue ellipticity (θ) using the software ACDP v2.9 [26] and compared with the software SDAR v2.9 [27] . The amount of TFE required to observe alpha-helical secondary structure is based on the appearance of a peak at 208 nm. For each peptide, secondary structure was predicted based on its amino acid sequence using the software PSIPRED [28] . 
ELISA
The wells of PVC micro-titer plates were coated with 100μl of a solution containing 500ng/ml peptide or protein diluted in 0.05M sodium carbonate coating buffer (pH 9.6). After incubation, the wells were blocked with 5% skim milk in PBS containing 0.05% Tween20 (PBS-T) and incubated at 37°C for 90 minutes, or overnight at 4°C. Two fold serial dilutions of sera were made and incubated at 37°C for 90 minutes. The sera were decanted and plate washed with PBS-T prior to addition of HRP conjugated goat anti-mouse secondary antibody (AbD Serotec) diluted 1:3000 in 0.5% skim milk/PBS-T. After incubating at 37°C for 90 minutes the plates were washed, o-Phenylenediamine Dihydrochloride was added to the wells, and incubated again at room temperature. The absorbance (450nm) was then measured. Antibody titers were defined as the reciprocal of the highest dilution of samples that yielded an optical density at 450nm of more than 3 standard deviations above the mean optical density of pre-immune sera. Statistically significant differences in ELISA titers were assessed using ANOVA and Kruskal Wallace non-parametric tests.
Immunofluorescent Microscopy
Immunofluorescent microscopy was carried out essentially as previously described [29] . Briefly, bacteria were grown overnight, washed, and fixed to a polylysine coated slide (ProSciTech) with 3% paraformaldehyde. The fixed slides were then blocked with 5% skim milk/ PBS-T. To prevent non-specific Fc-IgG binding by streptococcal surface proteins the slides were exposed to a second blocking step using non-specific human polyclonal IgG (AbD Serotec) was undertaken. The slides then were incubated with pooled murine antisera (1:200), washed, and incubated with secondary goat anti-mouse-IgG-FITC labelled antibody (Invitrogen, USA) diluted 1:200 in 0.5% skim milk/PBS-T. The slides were mounted in Prolong Gold (Life Technologies) and viewed with a 100x objective lens using a 473nm laser with absorbance of 500-650nm on an Olympus Fluoview FV1200 Confocal Laser Scanning microscope.
Western Blotting
Purified recombinant M-protein, porcine cardiac myosin (Sigma-Aldrich) and skeletal muscle tropomyosin (Sigma-Aldrich) were electrophoresed on 12% or 4-15% gradient SDS-PAGE gels, transferred to Hybond C nitrocellulose membranes (Amersham, USA), and blocked with 5% skim milk/PBS-T. The membranes were then incubated with murine anti-SV1 sera diluted 1:2000 in 5% skim milk/PBS-T, washed, and secondary goat anti-mouse IgG-HRP diluted 1:10,000 in PBS-T added. Following 60 min incubation, the membrane was washed, covered with chemiluminescent substrate (ECL Western Blotting Detection Reagent, Amersham) following manufactures instructions and exposed to standard X-ray film.
Immonosafety of SV1
The immuno-safety of SV1 was evaluated in a Lewis rat model of autoimmune valvulitis [30, 31] . Lewis rats (LEW/sSN; Albino: a,h,c: RT1) were purchased from the Animal Resources Centre (Canning Vale, Western Australia) and bred by sibling mating in Small Animal Breeding Facility at James Cook University (Townsville, Australia). For all immunisations rats were initially anaesthetised using 5% Isoflurane (Provet, Queensland, Australia) and 1-2 L/min O2. The Isoflurane level were subsequently maintained at 2% during immunization procedures. Following immunisation a local anaesthetic cream containing 25mg/g lignocaine and 25 mg/g prilocaine was applied to the injection site. Eight to twelve week-old female Lewis rats were subcutaneously immunized on day 0 in the hock of the hind left foot with 0.5 mg of SV1 or recombinant M5-protein emulsified with Complete Freund's Adjuvant (CFA), or intramuscularly with the same proteins admixed in 2% alum. Negative control rats were immunized with PBS in adjuvant. On days 1 and 3, the rats were intraperitoneally injected with 0.3μg Bordetella pertussis toxin (Sigma, Australia). Antigen boosts consisting of 0.5 mg of protein emulsified 1:1 with incomplete Freund's adjuvant, or admixed 2% alum were subcutaneously delivered on day 7. All animals were euthanased on day 21 by CO2 asphyxiation in a lethal chamber, followed by cervical dislocation. Blood, hearts and spleens were then collected.
To determine sera immunoglobulin G (IgG) reactivity, 10 μg/ml of M5, SV1, porcine cardiac myosin of collagen-1 (Sigma-Aldrich, St. Louis, MO) were coated onto Nunc Maxisorp plates (Roskilde, Denmark) overnight and test sera added with controls. A secondary goat antirat IgG (Abd Serotec) was used before OD was measured at 405nm in an ELISA plate reader. Mononuclear cells were aseptically isolated from spleens and T cell proliferation assays performed. Mononuclear cells from each group of rats were cultured in triplicate at 10 5 cells/well in RPMI-1640 culture medium with supplement. Cells were stimulated by the addition of 10 μg/ml SV1, M5, porcine cardiac myosin or collagen type 1 or 5 μg/ml concanavalin A (ConA). The cells were pulsed with 0.25 μCi 3H-thymidine (GEHealthcare, Australia), harvested onto filter mats, and counts per minute (CPM) determined using a Microlux beta scintillation counter [25, 26] . Proliferative responses are reported as the change in CPM between stimulated and unstimulated cells. Histological studies on cardiac tissue were carried out on rat hearts fixed in neutral buffered formalin and embedded in paraffin. Sections were stained with hematoxylin and eosin (H&E) and examined under a light microscope for evidence of valvulitis. All experiments using the rat model of valvulitis were approved by the James Cook University Ethics Committee (A1688).
FACS analysis
FACS was used to assess the binding of anti-sera to the surface of three GAS isolates that differed in their capsule expression levels [19] . GAS 5448 is an emm1 clinical isolate associated with invasive disease outbreaks [32] . GAS 5448AP is a hypervirulent derivative of GAS 5448 that, due a CovRS mutation, overexpresses capsule [33, 34] . GAS ΔhasA possesses a mutation in the capsular encoding hasA genes, resulting in abrogation of capsule expression. Bacteria were grown to mid log-phase, washed in PBS, and then incubated with human IgG in 0.3% BSA/PBS/Tween to block non-specific binding. The cells were sequentially incubated with primary antibody, followed by secondary goat anti-mouse FITC conjugated IgG, washed and fixed in 4% paraformaldehyde. Fluorescence was measured using a FACSort flow cytometer, and mean fluorescence intensity (MFI) determined. Statistical significant differences in MFI between PBS and experimental groups was subsequently assessed using by t-test.
Results
J14 i -variants present in SV1 are common in 97% of 173 emm-types
The selection of the J14 i variants present in SV1 was originally made after the examination of genes representing 77 different emm-types that were present in the Genbank database [19] . A subsequent study of emm-gene sequences of greater than 1000 globally distributed GAS isolates provided the opportunity to expand the analysis of the coverage of J14 i variants represented in SV1 to a larger dataset that include 173 unique emm-genes [23] . As the earlier study showed that the C-terminal amino acid sequences to be highly conserved within an emm-type, and to avoid bias due to over-representation, individual representatives of each emm-type were selected for the current analysis. Of the 173 unique emm-genes, all but five (emm134, emm174, emm137, emm205 and emm211) contained at least one of the J14 i variants represent in SV1 (S1 Table) . Sixty (35%) of these putative M-proteins possessed one variant, 90 (52%) possessed two variants, and 18 (10%) possessed three of these variants. J14 i .0 and J14 i .1 were the two most common variants, present in 43% and 51% of emm-types respectively. J14 i .2, J14 i .4 and J14 i .29 were present in 41%, 21% and 12% of the emm-types respectively. These latter three variants were the most prevalent J14 i variants in CRU1, the CRU most distant from the bacterial surface (Table 3 ). J14 i .0 was only found in the CRU1. Finally, 512 individual CRUs were present within the 173 M-proteins analyzed. Of these, 422 possessed a J14 i variant present in SV1. Together these results demonstrate that J14 i sequences present in SV1 are present in 97% of the emm-types examined in this study, and account for the majority of all J14 i sequences.
SV1 antibodies recognize multiple J14 i variants
To show that anti-SV1 antibodies did actually recognise and bind to the individual J14 i variants represented in the vaccine, sera collected after final immunisation of mice was used in ELISA against a panel of J14 i variant peptide sequences (Fig 2) . The panel included the variants ). There were no significant differences between the mean titers observed for these two peptides, and those observed with any of the peptides presents in SV1 as determined using by ANOVA and Kruskal Wallace non-parametric test. Titers against the remaining three other peptides (J14 i .12, J14 i .36 J14 i .53) were lower, but still significantly higher than titers observed for PBS sera negative control sera. Together these results demonstrate anti-SV1 antibodies are capable of recognizing multiple J14 i variants, increasing targets for SV1 antibodies on the bacterial surface, and potentially increasing the emm-type coverage afforded by SV1.
To determine which variants present of SV1 contribute to cross-recognition, antisera were raised against J14 i peptides. As individual J14 i peptides are poorly immunogenic, the J14 i peptides were resynthesized with GCN4 flanking amino acid sequences, designed to maintain the alpha-helical conformation of the parental M-protein, and conjugated to diphtheria toxoid prior to immunization of mice. Sera from individual mice in each group were then pooled and used in ELISAs against the panel of 10 J14 i variant peptides. For these assays, a titer of 1000 was chosen as an arbitrary cut-off value representing low or no binding between sera and peptide (Table 4) . As expected, antibody titers for individual sera were highest when used against the corresponding J14 i peptide sequence as capture antigen. Anti-J14 i .0 anti-sera also bound to J14 i .1, J14 i .2, J14 i .29 and J14 i .57. Titers for anti-J14 i .1 anti-sera were greater than 1000 against an additional two peptide sequences. Sera raised to J14 i .2 and J14 i .4 recognised 4 and 6 peptides respectively. Despite showing low titers against J14 i .29, anti-J14 i .29 anti-sera also bound to two peptides. Collectively, nine of the ten peptides examined were recognized by at least one of these peptide antisera. The differences in peptides recognized by the different anti-sera underscore the utility of incorporating multiple J14 i variants in a single construct.
To identify factors that may contribute to the cross-recognition, the percentage identity between J14 i peptides was determined (Table 5) , and compared to the corresponding ELISA titer (Fig 3) . This analysis has shown that for sera tested, there was a correlation between titer and relative identity between peptides. Using a titer of 1000 as the cut-off point as described above, cross-recognition was observed in 15 of 23 cases where the identity between J14 i pairs was greater than 70%, but only one instance amongst 23 pairs where the identity between sequences was less than 70%. 
Anti-SV1 antibodies recognize multiple M-proteins
The data above demonstrate that the design strategy for SV1 has resulted in a recombinant construct that is immunogenic and evokes antibody responses in the presence of a human approved adjuvant that theoretically should be capable of binding to the CRR of multiple Mproteins. To confirm this we subsequently conducted Western blots against eight M-proteins representing different emm-types and emm-type clusters. Binding was observed in all instances (Fig 4) . We also showed that SV1 antibodies bind to the surface of eight GAS strains expressing different M-proteins, but not to the emm-negative GAS JRS145 (Fig 4) .
Immuno-safety of SV1
The presence of cross-reactive epitopes within the M-protein has been a major hurdle for all M-protein vaccine development programs. The ability to demonstrate that immune responses raised against vaccine candidates do not induce immune responses that cross-react with human proteins and tissues is an important step before vaccines can proceed to human clinical trials. Here we first used Western blots using porcine cardiac myosin and skeletal muscle tropomyosin to show that antibodies from SV1 immunised mice failed to react with these proteins (S1 Fig). The rat autoimmune valvulitis model is the only animal model available that adequately mirrors the pathophysiological futures of RHD in humans. To provide a more robust safety assessment for SV1 as a vaccine candidate we used this model to investigate whether SV1 delivered in the presence of alum, a human approved adjuvant induced autoimmune inflammatory responses similar to that observed with RHD. For these experiments rats were immunized with PBS, recombinant M5 or SV1 in the presence of CFA. A second cohort of rats was immunized intramuscularly with the same antigens mixed with alum. Mean antibody titers to the immunizing antigen were greater than 10 5 for SV1 and M5 groups for both antigens (S2 Fig). Significant anti-M5 titers were also observed in sera from the SV1 immunized groups. In contrast titers to SV1 and M5 were less than 100 in the PBS control groups. No cross-reactive antibodies against cardiac myosin or collagen type 1 were detected in either M5 or SV1 immunized rat sera ( S2 Fig). T-cell responses to the vaccine were then assessed by measuring [ 3 H] incorporation in restimulation assays (Fig 5) . Splenic T cells from M5 immunized rats responded strongly to M5 restimulation irrespective of adjuvant used, weakly to SV1 restimulation, and did not respond to either cardiac myosin or collagen. Proliferative responses were greater to SV1 that M5 in the SV1/CFA immunized groups, but there were no differences in the SV1/alum immunized group. No T cell proliferative response to cardiac myosin or collagen was observed in either of the SV1 immunized groups.
Histological sections from SV1 immunized rats were compared to sections taken from M5-and PBS-immunized rats to determine whether the candidate SV1 vaccine induced inflammatory changes consistent with valvulitis or myocarditis. Four of the five rats immunized with M5/CFA had mild or moderate inflammation in the aortic and/or mitral valves. Inflammatory responses were absent in rats immunized with SV1 or PBS in Freund's adjuvant (Fig 5) . No inflammatory cell infiltrates were observed in of the groups where mice where immunized with antigen admixed with alum ( S2 Fig). 
Overexpression of capsule blocks antibody binding
Capsule is a major GAS virulence factor that, like the M-protein, also inhibits opsonophagocytosis. Total capsule expression levels differ between isolates [35, 36] , are up-regulated in different host niches [37] and have been reported to block antibody binding to GRAB, another bacterial protein located on the surface of GAS. Although we saw binding to the surface of GAS in all immunofluorescent assays, it is possible that overexpression of capsule may also block SV1 antibody binding. To test this hypothesis we used a FACS based assay to compare antibody binding to wild-type GAS 5448, a derivative that hyper-expresses capsule [33] and an acapsular GAS isolate (Fig 6) . In contrast to PBS sera, an increase in fluorescence was observed using anti-SV1 and anti-M1 sera against both the wild-type 5448 strain and ΔhasA acapsular mutant. However no significant difference in fluorescence was observed between the anti-PBS and anti-SV1 and anti-M1 sera when the hyper-encapsulated GAS 5448 AP and used in the same assay (p = 0.157).
Discussion
The greatest mortality associated with GAS infection occurs due to invasive disease and the autoimmune sequelae RF and RHD [1] . The burden of these diseases is greatest in developing nations and Indigenous communities within developed nations. Epidemiological studies in these populations show that multiple emm-types are often circulating, and there is also no association between emm-type and disease outcome [21] . Here we have shown that 168 of the 173 M-proteins examined possess a least one of the J14 i variants present in SV1. The number of emm-types examined represents a significant proportion of all known emm-types. The five M-proteins (emm134, emm174, emm137, emm205 and emm211) possessing variants not represented in SV1 all had atypical C-repeat regions. Four of these proteins only possessed two repeat units in their CRR, with a J14 i .12:J14 i .40 structure. The fifth only had a single CRU harboring J14 i .12. In the dataset analyzed here J14 i .12 was the seventh most common J14 i variant, present in thirteen different emm-types. As we showed that anti-SV1 antibodies bound to J14 i .12, it suggests that these emm-types would all be recognized by SV1 antisera post-vaccination. The epidemiological and cross-recognition data together suggest that in the absence of high levels of capsule on the bacterial surface, SV1 antibodies will be able to bind the surface of the majority, if not all circulating GAS emm-types.
The data reported here may also help to shed light on the coverage offered by other C-terminal GAS vaccines. Our data show that J14 i .0 is present in 43% of emm-types. However J14 i .0 antibodies were also shown to recognize J14 i .1, the most abundant J14 i variant, and J14 i .2, the third most common J14 i variant. The J8 peptide vaccine candidate includes 12 amino acids that are identical to 12 of the amino acids present in J14 i .0. This candidate and the corresponding J14 i sequence have both been shown to induce protective immune responses when conjugated to diphtheria toxoid or other molecules and provided the original rationale for targeting these sequences [16, 17] . Based on this analysis here we would predict J8-DT to also provide extended M-type coverage. The StreptInCor vaccine candidate developed by Guilherme et al incorporates a 55 amino acid construct from the C-terminal region from the M5 protein and includes both human B and T cell epitopes [15, 38] . StreptInCor contains the complete sequence of the relatively rare J14 i .6 sequence, and 12 amino acids at the C-terminus that are 100% identical to multiple J14 i variants. As we did not include J14 i .6 in our analysis here, we cannot conclusively demonstrate that this sequence will induce antibodies that recognize multiple J14 i variants. However given the extended length of the sequence, we believe that there is a strong possibility that it will. Antibodies to StreptInCore have recently been reported to be bactericidal towards five GAS strains [39] .
It is imperative that M protein based vaccine candidates do not to induce a deleterious autoimmune response following immunization. The rat model of valvulitis is a robust model that has allowed investigators to determine the development of inflammatory, immunopathological and functional changes in the rat heart that are akin to changes occurring in RHD in human [26] . Following exposure to M5 it has been shown that rat heart tissue including heart valves and the myocardium are infiltrated by inflammatory cells that include both macrophages and lymphocytes [25] . Here we tested SV1, when delivered with a human approved adjuvant, for its potential to cause autoimmune inflammatory changes that can be detected using this model. Our observations unequivocally demonstrated that SV1 does not cause any cardiac abnormalities such as those observed following M5 immunization. Therefore we conclude that SV1 is a safe vaccine candidate that does not have the capacity to induce an autoimmune response.
Finally our results also suggest that increased capsule production may influence the capacity of anti-SV1 antibodies to access antibody binding sites in the C-repeat region, a finding which may be also relevant to all GAS vaccine candidates targeting this and other surface antigens collagen. (C) Representative histology sections of Lewis rat cardiac tissues (x100 magnification) following immunization with recombinant M5-protein, SV1 or PBS with Freund's adjuvant. Areas of inflammation are indicated with a black arrow. A higher magnification image (x400) of an inflamed mitral valve from a rat immunized with M5 is shown. Mice that received PBS only or SV1 as antigen had no evidence of inflammatory changes in cardiac tissue. [40] . Historically, highly encapsulated strains of GAS are generally considered to be more virulent than isolates with expression lesser capsule, and are associated with rheumatic heart disease and invasive disease [36, 41] . The role that deployment of a GAS vaccine will play in the epidemiology of GAS is currently unknown. However as strains that expressing high levels of capsule are already circulating, the partial or complete blocking of antibody binding to these isolate may give them increased fitness when compared to strains expressing lesser amounts of capsule [35, 36] . Overcoming these potential limitations of CRR-targeting vaccines, and indeed all vaccine targeting proteins on the bacterial surface [13, [42] [43] [44] , remains a major challenge of GAS vaccine development. 
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